Skip to main content

Antiretroviral cause birth defect risk

HIV positive mothers can be a viral infection to protect their children, if they get antiretroviral drugs during pregnancy. However, even these drugs to prevent the spread of this disease are children, they may cause cleft lip and palate and other birth defects. A new study published in the Journal craniofacial cleft palate in January, will investigate the interaction between antiretroviral prophylaxis and cleft lip and palate.
To establish a drug and use the "report odds than the potential link between birth defects, the researchers studied five years of data from the U.S. Food and reporting system, Drug Administration of adverse events (AERS), pharmacovigilance database publicly available sources.
Antiretroviral drug therapy is to reduce the 15-25% of children the risk of transmission of HIV from mother to less than 1%, but even this success rate is now as a standard treatment with antiretroviral drugs, drugs not classified as safe as a class of drugs, the safety of use during pregnancy. Should therefore continue to investigate to assess the potential risks for the unborn child.
The results of this study identified 26 new cleft lip and cleft palate related to antiviral drugs, ie, lamivudine, efavirenz, nelfinavir, abacavir / as sulfate / laminudine, / zidovudine combination of events. Although the drug is reported to have high odds ratio, it is no evidence that they cause deformity, but they, as an indicator of a potential contact.
Cleft lip and palate is considered for several reasons, such as genetic and environmental factors, a genetic deformity. However, poor nutrition, excessive vitamin A intake and other vitamin and mineral deficiencies can also contribute to its development. Further research is needed to determine whether the association between antiretroviral drugs and cleft lip and palate.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more